- Home
- ABEV vs ONC Comparison
ABEV vs ONC Comparison
Compare ABEV & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEV
- ONC
- Stock Information
- Founded
- ABEV 1885
- ONC 2010
- Country
- ABEV Brazil
- ONC Switzerland
- Employees
- ABEV N/A
- ONC N/A
- Industry
- ABEV Beverages (Production/Distribution)
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- ABEV Consumer Staples
- ONC Health Care
- Exchange
- ABEV Nasdaq
- ONC Nasdaq
- Market Cap
- ABEV 33.8B
- ONC 37.3B
- IPO Year
- ABEV N/A
- ONC N/A
- Fundamental
- Price
- ABEV $2.18
- ONC $352.00
- Analyst Decision
- ABEV Hold
- ONC Strong Buy
- Analyst Count
- ABEV 4
- ONC 10
- Target Price
- ABEV $2.35
- ONC $344.70
- AVG Volume (30 Days)
- ABEV 41.5M
- ONC 230.5K
- Earning Date
- ABEV 10-30-2025
- ONC 11-11-2025
- Dividend Yield
- ABEV 7.98%
- ONC N/A
- EPS Growth
- ABEV 2.96
- ONC N/A
- EPS
- ABEV 0.17
- ONC N/A
- Revenue
- ABEV $16,833,014,419.00
- ONC $4,562,002,000.00
- Revenue This Year
- ABEV $5.86
- ONC $881.07
- Revenue Next Year
- ABEV $4.97
- ONC N/A
- P/E Ratio
- ABEV $12.63
- ONC N/A
- Revenue Growth
- ABEV 13.76
- ONC 47.33
- 52 Week Low
- ABEV $1.76
- ONC $170.99
- 52 Week High
- ABEV $2.64
- ONC $355.30
- Technical
- Relative Strength Index (RSI)
- ABEV 36.86
- ONC 62.34
- Support Level
- ABEV $2.17
- ONC $334.53
- Resistance Level
- ABEV $2.21
- ONC $355.30
- Average True Range (ATR)
- ABEV 0.04
- ONC 6.98
- MACD
- ABEV -0.02
- ONC 0.24
- Stochastic Oscillator
- ABEV 7.69
- ONC 84.37
About ABEV Ambev S.A.
Ambev is the largest brewer in Latin America and the Caribbean and is Anheuser-Busch InBev's subsidiary in the region. It produces, distributes, and sells beer and PepsiCo products in Brazil and other Latin American countries and owns Argentina's largest brewer, Quinsa. Ambev was formed in 1999 through the merger of Brazil's two largest beverage companies, Brahma and Antarctica. In 2004, Ambev combined with Canadian brewer Labatt, giving AB InBev a controlling interest of 62%.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.